Effects of dopamine agonists on neuropsychiatric symptoms of Parkinson's disease
Language English Country Switzerland Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
20224287
DOI
10.1159/000295665
PII: 000295665
Knihovny.cz E-resources
- MeSH
- Dopamine Agonists therapeutic use MeSH
- Depression diagnostic imaging drug therapy etiology MeSH
- Clinical Trials as Topic MeSH
- Cognition Disorders complications diagnostic imaging drug therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Neuropsychological Tests MeSH
- Parkinson Disease complications diagnostic imaging MeSH
- Psychiatric Status Rating Scales MeSH
- Radionuclide Imaging MeSH
- Iodine Radioisotopes pharmacokinetics MeSH
- Aged MeSH
- Tropanes pharmacokinetics MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane MeSH Browser
- Dopamine Agonists MeSH
- Iodine Radioisotopes MeSH
- Tropanes MeSH
The efficacy of dopamine (DA) agonists in the treatment of motor symptoms of Parkinson's disease (PD) has been clearly demonstrated. It has also been documented that DA agonists may have both a positive and a negative impact on neuropsychiatric symptoms in PD patients. This paper will focus on the effects of DA agonists on depressive and cognitive symptoms of PD.
References provided by Crossref.org
Long-term dopaminergic therapy improves spoken language in de-novo Parkinson's disease
Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study
